The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Rasilez HCT

300/12.5 milligram(s) Film-coated tablet

Noden Pharma DACEU/1/08/491/041-060

Main Information

Trade NameRasilez HCT
Active SubstancesAliskiren hemifumarate
Strength300/12.5 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderNoden Pharma DAC
Licence NumberEU/1/08/491/041-060

Group Information

ATC CodeC09XA52 aliskiren and hydrochlorothiazide


Licence Issued
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing Status


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back